Clinical Updates: Major Bleeding with Oral Anticoagulant Therapy
Track:
Education Sessions (CE)
Program Code: 341-L01
Date: Tuesday, December 10, 2013
Time: 9:00 AM to 11:00 AM EST
Location:
W304 F, Level 3
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
William Dager, PharmD, FCSHP, Pharmacist Specialist, University of California, Davis Medical Center
One of the major areas of patient care responsibilities for me has been the management of anticoagulation therapy, primarily in the inpatient setting. This has resulted in dozen of published manuscripts covering a wide number of related issues. I have also represented pharmacy on multi-disciplinary national events, and lectured on optimizing anticoagulation therapy. My practice setting has been highlighted in AJHP and by ACCP. Other related activities include serving as the chair of the editorial advisory board for The Annals of Pharmacotherapy panel on anticoagulation, and authored three chapters in the ASHP textbook on anticoagulation therapy edited by Michael Gulseth.
Other Academic Titles (without pay)
Clinical Professor of Pharmacy, UC San Francisco School of Pharmacy; Clinical Professor of Medicine, UC Davis School of Medicine.
Candice Garwood
Denise Rhoney
Maureen Smythe, PharmD, FCCP, Professor, Department of Pharmacy Practice, Wayne State University
I have established an expertise in inpatient anticoagulation through practice experience as well as through a practice based research program. I have spoken on the area of anticoagulation at numerous national meetings. I have published several papers addressing the controversies in heparin monitoring.
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Maureen Smythe, PharmD, FCCP, Professor, Department of Pharmacy Practice, Wayne State University
I have established an expertise in inpatient anticoagulation through practice experience as well as through a practice based research program. I have spoken on the area of anticoagulation at numerous national meetings. I have published several papers addressing the controversies in heparin monitoring.
Discuss consequences of major bleeding on anticoagulant therapy.
Evaluate major bleeding as an endpoint in anticoagulant trials.
Interpret available data on major bleeding with warfarin and novel oral anticoagulants.
Recommend a protocol for managing life threatening bleeding with novel oral anticoagulants.